Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers

Publication date: Dec 05, 2023

Notably, among the 83 patients with locally advanced disease, the complete response rate in the RP1 plus cemiplimab group was 48. 1% versus 22. 6% in the cemiplimab only group. For those patients with tumor burden greater than 10 cm, CRR was 21. 9% in the RP1 plus cemiplimab group versus 11. 1% in the cemiplimab only group. Data are also included for 16 patients from the initial cohort representing a total of 156 patients in this treatment setting. In this cohort, responses were seen across disease stages, including complete responses in patients with stage IVM1b/c disease. The ORR was comparable between the two study groups (52. 5% for RP1 plus cemiplimab vs. 51. 4% for cemiplimab alone, p=0. 692). After following all patients for at least 12 months and pending central review by RECIST v1. 1, BLA submission for RP1 in combination with nivolumab is planned for 2H 2022. The study did not meet either of the two primary endpoints of complete response rate (CRR) or overall response rate (ORR) as assessed by blinded independent central review.

Concepts Keywords
2026company Anti
Carcinoma Cemiplimab
Newswire Clinical
Settingsportfolio Cohort
Short Combination
Failed
Group
Ignyte
Melanoma
Nivolumab
Pd1
Rp1
Skin
Treatment
Trial

Semantics

Type Source Name
disease MESH hepatocellular carcinoma
pathway KEGG Hepatocellular carcinoma
pathway KEGG Colorectal cancer
disease MESH colorectal cancer
disease MESH squamous cell carcinoma of the head and neck
disease MESH uveal melanoma
pathway KEGG Basal cell carcinoma
disease MESH angiosarcoma
pathway REACTOME Release
disease MESH basal cell carcinoma
drug DRUGBANK MCC
pathway KEGG Allograft rejection
disease MESH immunocompromised patients
drug DRUGBANK Coenzyme M
disease MESH cytokine release syndrome
disease MESH injection site reaction
disease MESH myocarditis
drug DRUGBANK Ipilimumab
disease MESH influenza
disease MESH hypothyroidism
drug DRUGBANK Aspartame
disease MESH tumors
drug DRUGBANK Nivolumab
disease MESH squamous cell carcinoma
drug DRUGBANK Nonoxynol-9
disease MESH skin cancers
pathway KEGG Melanoma
disease MESH melanoma
drug DRUGBANK Cemiplimab
disease MESH hepatitis

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *